Juno Therapeutics, Inc. Overview
Pro stress-test →Founded in 2013 with a focus on chimeric antigen receptor (CAR) T-cell therapies, Juno quickly established itself as a pioneer in leveraging genetically engineered T-cells for cancer treatment. Now a wholly owned subsidiary of Bristol Myers Squibb, Juno operates as a leading cell therapy unit within one of the world's largest biopharmaceutical companies.
Strategic Profile
Pro stress-test →Juno is an integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer, having developed cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Following Bristol-Myers Squibb's completion of its acquisition of Celgene in November 2019, Juno has been integrated into BMS's oncology and cell therapy portfolio, positioning it to leverage the parent company's scale and resources.
Competitive Landscape
Pro stress-test →Juno competes within the CAR-T cell therapy and advanced cellular immunotherapy space against Kite Pharma (Gilead), Novartis, Celldex, Autolus, and emerging private cell therapy companies. As a BMS subsidiary, Juno's competitive positioning is strengthened by parent company resources, manufacturing scale, and global commercialization infrastructure, though it faces intense competition in CAR-T approvals and next-generation cell therapy approaches.
Industry Context
Juno Therapeutics, Inc. operates in CAR-T cell therapy and cellular immunotherapy.
Key facts
Founded: 2013 · Headquarters: Seattle, US · Revenue: N/A · Market cap: N/A